• Treffer 1 von 1
Zurück zur Trefferliste

Organoid Models for Cancer Research — From Bed to Bench Side and Back

Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-246307
  • Simple Summary Despite significant strides in multimodal therapy, cancers still rank within the first three causes of death especially in industrial nations. A lack of individualized approaches and accurate preclinical models are amongst the major barriers that limit the development of novel therapeutic options and drugs. Recently, the 3D culture system of organoids was developed which stably retains the genetic and phenotypic characteristics of the original tissue, healthy as well as diseased. In this review, we summarize current data andSimple Summary Despite significant strides in multimodal therapy, cancers still rank within the first three causes of death especially in industrial nations. A lack of individualized approaches and accurate preclinical models are amongst the major barriers that limit the development of novel therapeutic options and drugs. Recently, the 3D culture system of organoids was developed which stably retains the genetic and phenotypic characteristics of the original tissue, healthy as well as diseased. In this review, we summarize current data and evidence on the relevance and reliability of such organoid culture systems in cancer research, focusing on their role in drug investigations (in a personalized manner). Abstract Organoids are a new 3D ex vivo culture system that have been applied in various fields of biomedical research. First isolated from the murine small intestine, they have since been established from a wide range of organs and tissues, both in healthy and diseased states. Organoids genetically, functionally and phenotypically retain the characteristics of their tissue of origin even after multiple passages, making them a valuable tool in studying various physiologic and pathophysiologic processes. The finding that organoids can also be established from tumor tissue or can be engineered to recapitulate tumor tissue has dramatically increased their use in cancer research. In this review, we discuss the potential of organoids to close the gap between preclinical in vitro and in vivo models as well as clinical trials in cancer research focusing on drug investigation and development.zeige mehrzeige weniger

Volltext Dateien herunterladen

Metadaten exportieren

Weitere Dienste

Teilen auf Twitter Suche bei Google Scholar Statistik - Anzahl der Zugriffe auf das Dokument
Metadaten
Autor(en): Carolin Kastner, Anne Hendricks, Hanna Deinlein, Mohammed Hankir, Christoph-Thomas Germer, Stefanie Schmidt, Armin Wiegering
URN:urn:nbn:de:bvb:20-opus-246307
Dokumentart:Artikel / Aufsatz in einer Zeitschrift
Institute der Universität:Medizinische Fakultät / Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I)
Medizinische Fakultät / Theodor-Boveri-Institut für Biowissenschaften
Sprache der Veröffentlichung:Englisch
Titel des übergeordneten Werkes / der Zeitschrift (Englisch):Cancers
ISSN:2072-6694
Erscheinungsjahr:2021
Band / Jahrgang:13
Heft / Ausgabe:19
Aufsatznummer:4812
Originalveröffentlichung / Quelle:Cancers 2021, 13(19), 4812; https://doi.org/10.3390/cancers13194812
DOI:https://doi.org/10.3390/cancers13194812
Allgemeine fachliche Zuordnung (DDC-Klassifikation):6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 617 Chirurgie und verwandte medizinische Fachrichtungen
Freie Schlagwort(e):cancer; organoid; patient-derived organoid (PDOs); patient-derived tumor organoid (PDTO); tumor disease
Datum der Freischaltung:11.01.2022
Datum der Erstveröffentlichung:26.09.2021
Open-Access-Publikationsfonds / Förderzeitraum 2021
Lizenz (Deutsch):License LogoCC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International